Irma Bagdoniene։ Why Intensive Prevention is the Most Rational Strategy in Preventive Cardiology
Irma Bagdoniene, Cardiologist Specializing in Prevention & Lipidology, shared on LinkedIn about a recent article by Jennifer G. Robinson et al, published in Journal of the American Heart Association:
”Is early, intensive prevention ‘aggressive’? It’s not. On World Logic Day, it just makes sense.
I often tell my patients:
The human body follows simple logic.
In preventive cardiology, clinical inertia is a common barrier. But the evidence to avoid delays is overwhelming. This is the basis of our ‘strike early, strike strong’ strategy:
- The logic of time: Atherosclerosis results from cumulative exposure. It’s the total LDL burden over decades—the “mg-years”—that defines risk. The sooner we act, the more years we protect.
- The logic of causality: LDL cholesterol is a proven causal factor in ASCVD. Mendelian randomization studies and large clinical trials consistently confirm this. Lowering LDL prevents downstream events.
- The logic of measurement: We cannot manage what we don’t detect. Risk scores alone fall short. Advanced assessments like CACS, CCTA, Lp(a), and ApoB provide clear evidence of subclinical disease—calling for early intervention.
The conclusion is simple. The evidence and tools are ready. Early application is the most rational approach to stopping heart attacks before they occur.
Prevention is not aggressive—it is the sensible choice.
On World Logic Day (Jan 14), proclaimed by UNESCO, a reminder:
Good medicine is often just good logic!”
Title: Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
Authors: Jennifer G. Robinson, Kevin Jon Williams, Samuel Gidding, Jan Borén, Ira Tabas, Edward A. Fisher, Chris Packard, Michael Pencina, Zahi A. Fayad, Venkatesh Mani, Kerry Anne Rye, Børge G. Nordestgaard, Anne Tybjærg-Hansen, Pamela S. Douglas, Stephen J. Nicholls, Neha Pagidipati, Allan Sniderman
Read the Full Article on Journal of the American Heart Association․

Stay updated on all scientific advances with Hemostasis Today.
-
Feb 8, 2026, 15:09Alexandra Heumber Perry: Rare Diseases as a Measure of Equity and Multilateralism in Global Health
-
Feb 8, 2026, 14:59Heghine Khachatryan: Ensuring Safe Pregnancy in Women with Glanzmann Thrombasthenia
-
Feb 8, 2026, 14:54Gustavo Monnerat: New Evidence on Adverse Effects Attributed to Statin Therapy
-
Feb 8, 2026, 14:40Mona Alfaraj: Therapeutic Apheresis Case Series in Sickle Cell Disease with Fat Embolism Syndrome
-
Feb 8, 2026, 14:27Sandra Revill Tremulis: The Major Trial Testing Whether Lp(a) Lowering Saves Lives
-
Feb 8, 2026, 14:09Mashukur Rahman: New ESC Dyslipidemia Updates Expand the Role of Statins
-
Feb 8, 2026, 13:58Alan Nurden: A “Gold Medal” Study on Silk Fibroin 3D Models for Bone Marrow Fibrosis
-
Feb 8, 2026, 13:45Shinya Goto։ New Lancet Meta-Analysis on Statin-Related Adverse Effects
-
Feb 8, 2026, 13:29Andrea Marshall: Highlighting the Impact of PBM Conference 2026 on Patient-Centred Blood Care